Skip to main content

LCD L38026: Corneal Hysteresis

LCD L38026, Corneal Hysteresis, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2026-08-13 and first in force 2019-10-21. The policy text runs 25 words. 2 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 0 covered ICD-10-CM codes: the same total as L38014 (Wellpoint Federal, 0 codes, revised 2026-04-01) and the same total as L38211 (Wisconsin Physicians Service Insurance Corporation, 0 codes, revised 2026-05-28).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2026-08-13
Original effective
2019-10-21
Policy text
25 words
Covered ICD-10 codes (articles)
0

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L38026
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Coverage indications, limitations and medical necessity

This is a NON-coverage policy for all corneal hysteresis (CH) assessments as a means of risk assessment or monitoring for progression of ophthalmic disease activity.

Summary of evidence (opening)

Hysteresis is a measure of resistance to deformation to an applied force. CH is a measure of the viscoelastic dampening property of the cornea and is postulated to be a surrogate for the viscoelastic dampening properties of the posterior sclera and lamina cribrosa through which the retinal ganglion cell axons pass as they exit the eye. It has been theorized that glaucomatous damage to the retinal ganglion cell axons occurs at the lamina cribrosa and that viscoelastic differences in the lamina cribrosa are responsible for differential effects of intraocular pressure (IOP) within these tissues and contribute to the susceptibility to IOP-mediated damage. Studies show an association between a lower CH and glaucoma or glaucoma risk, and it has been proposed as a risk stratification tool for use in the treatment of glaucoma, glaucoma suspect, and ocular hypertension (OHT). CH is not itself a modifiable risk factor for glaucoma but theoretically could signal the need for more aggressive IOP reduction.

The Ocular Response Analyzer (ORA) (Reichert Inc., Buffalo, New York, USA) is a non-contact tonometer that measures CH. The ORA received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2004 for the intended use of measurement of IOP and biomechanical response of the cornea “for the purpose of aiding in the diagnosis and monitoring of glaucoma.” 1 This device measures CH by measuring the difference of 2 applanation event pressures taken during the inward and outward movement of the cornea following delivery of a metered pulse of air.

A 2006 retrospective, observational study compared CH and central corneal thickness (CCT) on various indices of glaucomatous damage in 230 patients (mean 65 years), 85% diagnosed with primary open angle glaucoma (POAG) or glaucoma suspect, and 15% with angle-closure glaucoma, suspected angle-closure glaucoma, or secondary glaucoma. 2 Multivariate analysis found CCT, but not CH to be predictive of higher cup-to-disk ratio (CDR) (P=0.02 vs. P=0.36). Multivariate analysis found lower CH but not CCT to be predictive of visual field progression (P=0.30), but not after factoring in axial length (P=0.09). Neither CH nor CCT were significantly associated with worsening mean deviation (MD) or pattern standard deviation (PSD). A 2011 prospective observational study of 162 POAG subjects found no statistical difference in CH compared with 150 normal subjects. 3 A small (57 patients), 2012 retrospective study found both CH and IOP to be independent, statistically significant predictors of response to topical prostaglandin treatment. 4

A 2012 prospective cohort study of 153 patients (153 eyes) with established glaucoma evaluated the relationship between CCT and CH and their correlation with progressive visual field loss. 5 Baseline measurements included age, race, sex, CH, MD, PSD, CCT, and IOP (calculated by averaging the first 4 measurements following the baseline visual field (VF)), peak IOP, and corneal compensated IOP (IOPcc). Progression of glaucoma was determined by an automated pointwise linear regression analysis of visual field tests. Progression occurred in 25 enrolled eyes (16%) and demonstrated significantly lower CCT and CH compared with non-progressed eyes (p=0.04 and p A 2013 retrospective study of 131 glaucoma patients investigated the correlation between CH and other structural markers of glaucomatous damage on spectral domain optical coherence tomography (SDOCT). 6 In a multivariable analysis including MD, age, average retinal nerve fiber layer (RNFL) thickness, and glaucoma status, only MD (p=0.001) and age (p A 2017 cross sectional study compared single CH measurements among 123 patients (123 eyes) previously diagnosed with either glaucoma (high tension glaucoma, N=37; pseudoexfoliative glaucoma, N=12; normal tension glaucoma, N=24), OHT (N=28), or glaucoma-like optic discs (GLD) (N=22). 7 A one-way Analysis of Covariance (ANCOVA), correcting for differences in age and IOP, found mean CH to be significantly lower in patients with glaucoma versus those with OHT and GLD (p The following 4 studies by the same principal investigator included subjects who were part of the larger Diagnostic Innovations in Glaucoma Study (DIGS). 8-11 DIGS is a single-center, prospective, longitudinal cohort study of the relationships between optic nerve structure and glaucomatous vision loss, and the assessment of new diagnostic and monitoring modalities that could be used to mitigate functional vision loss by identifying at-risk patients through earlier detection and intervention.

The contractor cites 26 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2019-10-21
Current revision effective
2026-08-13
Last reviewed by the contractor
2026-08-04
MCD version
30

Other related documents: A56968 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L38026 cover?

This is a NON-coverage policy for all corneal hysteresis (CH) assessments as a means of risk assessment or monitoring for progression of ophthalmic disease activity. The full 25-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L38026 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 2 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L38026?

The current export links no billing and coding article with a diagnosis list to LCD L38026, so Palmetto GBA decides coverage on the 25-word policy text and the documentation in the record rather than by an automated diagnosis edit.

How do I appeal a denial under LCD L38026?

A denial under LCD L38026 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.